Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (up 258.5% year over year) with net income of −$119M.
Q3 2026 key financials · XBRL
- Revenue
- $19M
- +258.5% YoY · +141.8% QoQ
- Net income
- −$119M
- +26.6% YoY · +9.1% QoQ
- Operating margin
- -664.0%
- EPS (diluted)
- −$0.22
- +38.9% YoY · +12.0% QoQ
Source: XBRL data from the RECURSION PHARMACEUTICALS, INC. (RXRX) Q3 2026 10-Q on SEC EDGAR. USD.
RECURSION PHARMACEUTICALS, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $18.6M, up over 100% YoY from $5.2M, driven by a $10.0M Sanofi milestone
- Net loss $119.0M vs $162.3M YoY, with operating loss $123.2M vs $172.2M
- Best R&D performer: REC-4881 spending $5.8M, up over 100% YoY; worst: internal and partnered discovery, $8.7M, down 75%
- Cash, equivalents and restricted cash $561.5M vs $753.9M at December 31, 2025; operating cash use $264.5M
- Registrational REC-4881 trial anticipated in second half of 2027; additional financing expected in the future
Risk Factors
- No material changes disclosed from the 2025 Annual Report risk factors
- Key carried-forward risk: common stock investment involves a high degree of risk
- Detailed risks remain in Part I, Item 1A of the 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RECURSION PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.